---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-022992"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:41:54.347376+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Interpace Q2 revenue $9.4M (-16% YoY), net loss $3.9M on ThyGeNEXT price cut

## Summary
- Q2 net revenue $9.4M, down 16% YoY; net loss $3.9M vs $3.4M prior year.
- Adjusted EBITDA $(2.9)M vs $(0.3)M; gross margin 37% vs 48% due to 70% retroactive ThyGeNEXT price cut.
- Cash balance fell to $1.9M at June 30 from $3.8M year ago; DSO improved 15% to 59 days.
- Launched Point2Glucose test; YTD net loss improved $1.5M to $(6.1)M; new thyroid data published.

## SEC filing metadata
- accession: 0001493152-22-022992
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222022992/0001493152-22-022992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222022992/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-022992
- JSON: https://secwatch.observer/filing/0001493152-22-022992.json
- Plain text: https://secwatch.observer/filing/0001493152-22-022992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.